课题基金 / 基金详情

Non-Human Primate Models to Evaluate Therapeutic Strats and Topical Microbicides

Non-Human Primate Models to Evaluate Therapeutic Strats and Topical Microbicides
用于评估治疗策略和局部杀菌剂的非人类灵长类动物模型
批准号:
8602495
负责人:
NANCY LIN
金额:
$360.67万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-06-01 至 2013-05-31

项目摘要

项目成果

NANCY LIN的其他基金

相似基金

相关文献

中文摘要
翻译
该合同的目的是提供一个资源,以评估治疗剂/策略和局部杀微生物剂在SIV/SHIV猕猴动物模型。用于评价的研究产品将由研究产品的申办者或通过NIAID提供给承包商。项目官员将选择要进行的研究,包括: 证实在其他动物模型中证明有前途的候选物/干预措施的有效性 概念验证研究,有可能促进代理或策略的开发 在其他HIV感染动物模型中无法进行的评估 开发新的和改进的SIV/SHIV猕猴动物模型 治疗剂和杀微生物剂在非人类灵长类动物和人类细胞中的疗效和毒性的体外评估
英文摘要
The objective of this contract is to provide a resource to evaluate therapeutic agents/strategies and topical microbicides in SIV/SHIV macaque animal models. Study products for evaluation will be provided to the Contractor by the sponsor of the study product or through the NIAID. The Project Officer will select the studies to be performed, to include: ¿ Confirmation of efficacy of candidates/interventions that have proved promising in other animal models ¿ Proof-of-concept studies with the potential to advance development of an agent or strategy ¿ Evaluations that cannot be done in other animal models of HIV infection ¿ Development of new and improved SIV/SHIV macaque animal models ¿ In vitro assessment of efficacy and toxicity of therapeutic agents and microbicides in non-human primate and human cells
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NIAID PRECLINICAL DEVELOPMENT SUPPORT - PRODUCTION OF HIV-1 gp120 PROTEIN
NIAID PRECLINICAL DEVELOPMENT SUPPORT - TOXICITY TESTING FOR CH505 T/F GP120 PROTEIN
NIAID PRECLINICAL DEVELOPMENT SUPPORT - PRODUCTION OF HCMV-TR3∆PP71 HIVGAG FOR CLINICAL TRIALS
NIAID PRECLINICAL DEVELOPMENT SUPPORT - PRODUCTION OF MHRP GP145 CLADE C PROTEIN
海外基金